Product Description
brilacidin, a defensin mimetic, with potential antimicrobial and anti-mucositic activities. Upon rinsing with the brilacidin oral rinse, brilacidin imitates defensin as a human host defense protein (HDP), and binds to and disrupts the bacterial cell membrane.
Mechanisms of Action: PDE4 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: Fast Track - COVID-19 *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Innovation Pharmaceuticals, Inc.
Company Location: WAKEFIELD MA 01880
Company CEO: Leo Ehrlich
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Communicable Diseases|Skin Diseases, Bacterial|COVID-19|Mucositis|Stomatitis|Head and Neck Cancer|Cellulitis|Skin Diseases, Infectious
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| IPI-BRIc-201 | P2 |
Completed |
COVID-19 |
2021-07-01 |
|
| BC250 | P1 |
Completed |
Healthy Volunteers |
2020-02-12 |
27% |
| Brilacidin | P2 |
Completed |
Mucositis|Head and Neck Cancer|Stomatitis |
2017-10-25 |
|
| CTIX-BRI-204 | P2 |
Completed |
Skin Diseases, Bacterial|Cellulitis|Communicable Diseases|Skin Diseases, Infectious |
2014-10-01 |